Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
暂无分享,去创建一个
E. Berns | M. Smid | M. Jansen | Marcel Smid | Jozien Helleman | M. van der Burg | J. Helleman | Els M.J.J. Berns | Maurice P.H.M. Jansen | Maria E.L. van der Burg
[1] J. Massagué,et al. The logic of TGFβ signaling , 2006 .
[2] E. Berns,et al. TP53 and ovarian cancer , 2003, Human mutation.
[3] A. Jemal,et al. Global Cancer Statistics , 2011 .
[4] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[5] Anil K Sood,et al. Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] F. Slack,et al. let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.
[7] Tak-Hong Cheung,et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. , 2004, Cancer genetics and cytogenetics.
[8] Dong Wang,et al. Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.
[9] R. Ochs,et al. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells , 2005, Molecular Cancer Therapeutics.
[10] A. Addario,et al. Role of microRNAs in drug-resistant ovarian cancer cells. , 2008, Gynecologic oncology.
[11] S. Kaye,et al. Ovarian cancer: progress and continuing controversies in management. , 2002, European journal of cancer.
[12] Bernard Têtu,et al. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. , 2006, International journal of oncology.
[13] S. Cannistra. Cancer of the ovary. , 1993, The New England journal of medicine.
[14] A. Mercurio,et al. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. , 2003, Molecular biology of the cell.
[15] M. Buyse,et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.
[16] S. Rosenwald,et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.
[17] Javed Khan,et al. Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers , 2005, Clinical Cancer Research.
[18] Robert C. Bast,et al. The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.
[19] S. Cannistra,et al. Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.
[20] H. Dressman,et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. , 2009, Gynecologic oncology.
[21] J. Lieberman,et al. let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.
[22] Joel Greshock,et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.
[23] J. Massagué,et al. The logic of TGFbeta signaling. , 2006, FEBS letters.
[24] W. Dalton,et al. Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies , 2004, Cancer and Metastasis Reviews.
[25] Maurice P H M Jansen,et al. Molecular profiling of platinum resistant ovarian cancer , 2006, International journal of cancer.
[26] Christopher Haslett,et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.
[27] Jacqueline A. Hall,et al. Critical evaluation of p53 as a prognostic marker in ovarian cancer , 2004, Expert Reviews in Molecular Medicine.
[28] Anil Potti,et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Gunaratne. Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells? , 2009, Current stem cell research & therapy.
[30] M. Gore,et al. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.
[31] K. Nephew,et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. , 2009, BMC medical genomics.
[32] Douglas A Levine,et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Libermann,et al. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer , 2008, BMC Medical Genomics.
[34] A. Berchuck,et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] K. Tsuchida,et al. Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.
[36] P. Wong,et al. Dual roles of Nrf2 in cancer. , 2008, Pharmacological research.
[37] Kathryn A. O’Donnell,et al. c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.
[38] David I. Smith,et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.
[39] Carsten Denkert,et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. , 2009, Cancer research.
[40] S. Minkin,et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.
[41] Bonnie F. Sloane,et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. , 2004, The American journal of pathology.